http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6140024-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4423185f79003e8f9b981e29323454a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 |
| filingDate | 2009-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17010087617e259300a443272f1004f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c521eeb0991900ac3dc99d191ac694a1 |
| publicationDate | 2010-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6140024-A2 |
| titleOfInvention | USE OF PI3K-ALFA QUINAXOLINE INHIBITING COMPOUNDS FOR CANCER TREATMENT |
| abstract | 1.- Use of a compound of Formula I: or a simple isomer thereof, where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof, for manufacturing of a medicament characterized in that said medicament is for the treatment of cancer and contains the compound of Formula I and at least one of a pharmaceutically acceptable carrier, excipient or diluent in combination with, one or more chemotherapeutic agents, one or more of the hormonal therapies , one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation where the Compound of Formula I is this where: W1, W2, W3, and W4 are -C (R1) =; or one or two of W1, W2, W3, and W4 are independently -N = and the remaining are (R1) =; and where each R1 is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino; R51 is hydrogen or alkyl; R52 is hydrogen or halo; R50, R53, and R54 are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, -N (R55) C (O) -C1 alkylene -C6-N (R55a) R55b, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, -S (O) 2NR55R55a, or alkylcarbonylamino and where R55 and R55b are independently hydrogen, alkyl, or alkenyl and R55a is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or R53 and R54 together with the carbons to which they are attached form a 5 or 6 membered heteroaryl or 5 or 6 membered heterocycloalkyl; B is phenyl substituted with R3a and optionally also substituted with one, two or three R3; or B is heteroaryl optionally substituted with one, two or three R3, R3a is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; ... |
| priorityDate | 2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.